Daxor Corporation
DXR
Positions held
Your positionsDXR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $61.07M | Enterprise value | — | Trailing P/E | 9.51 | Forward P/E | — |
| PEG | — | Price / book | 1.18 | Beta | 0.35 | Dividend yield | 0.00% |
| Revenue growth | 25.5% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -45.3% |
| Profit margin | 198.6% | ROE | 14.2% | ROA | -2.6% | Debt / equity | — |
| Current ratio | 2.88 | Free cash flow | $333,869 | Analyst recommendation | none | Mean target | $20.00 |
| 52w high | $14.76 | 52w low | $8.56 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $10.3M | $2.1M | $1.3M | $6.3M |
| Op margin | — | — | — | — |
| Net income | $9.2M | $0.5M | $0.3M | $5.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-01 · Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
2026-09-08 · Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference
2026-09-01 · Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter
2026-07-30 · Daxor Launches Blood Testing Lab in Eastern Kansis
2026-07-30 · Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas
2026-07-21 · Dynamic announces July 2026 cash distributions for Dynamic Active ETFs and ETF Series
Price (daily)
Full chart · RSI · MACD · patterns